WAHLGREN et al. S.N. 09/508,967

comprising an amino-terminal part of the sequence according to SEQ ID NO:1, wherein said amino terminal part is domain DBL-1, and wherein said polypeptide is capable of binding to a negatively charged heparan sulfate or heparan sulfate-like molecule.--

Amend claim 14 as follows:

--14. (twice amended) A polypeptide originating from a malaria erythrocyte membrane protein comprising domain DBL-1 having about 400-500 amino acids of the sequence according to SEQ ID NO:1.--

Please cancel claim 15.

Amend claim 33 as follows:

--33. (twice amended) A medicament made from a polypeptide originating from a malaria erythrocyte membrane protein comprising an amino-terminal part of the sequence according to SEQ ID NO:1, wherein said amino terminal part is domain DBL-1, and wherein said polypeptide is capable of binding to a negatively charged heparan sulfate or heparan sulfate-like molecule.--

Amend claim 35 as follows:

--35. (twice amended) An isolated polypeptide originating from a malaria erythrocyte membrane protein comprising an amino-terminal part of the sequence according to SEQ ID NO:1, wherein said amino terminal part is domain DBL-1, and wherein the polypeptides bind to malaria-infected

WAHLGREN et al. S.N. 09/508,967



erythrocytes membrane protein, and wherein said polypeptide is capable of binding to a negatively charged heparan sulfate or heparan sulfate-like molecule.--

Please cancel claim 36.

Amend claim 38 as follows:





--38. (amended) A composition comprising and adjuvant and a polypeptide according to claim 13.--

REMARKS

While Applicants believe that the present application has been amended in a manner that places it in condition for allowance at the time of the next Official Action, Applicants believe that an interview would advance prosecution and allow Applicants to emphasize the merits of the claimed invention.

Accordingly, Applicant would like to request an interview with the Examiner of the above-identified application. Applicants originally contacted Supervisory Patent Examiner (SPE) Smith to arrange an interview in the present application. However, SPE Smith indicated that a new Examiner will be put in charge of the present application. As such, she recommended that we file a response and follow up the response with an interview with the new Examiner of the present application. The Examiner is invited to contact the undersigned agent to arrange an interview. Otherwise, Applicants will follow up this amendment with a telephone call to discuss the possibility of arranging an interview.